Nektar Therapeutics
NKTR
181 hedge funds and large institutions have $1.73B invested in Nektar Therapeutics in 2015 Q2 according to their latest regulatory filings, with 51 funds opening new positions, 53 increasing their positions, 45 reducing their positions, and 23 closing their positions.
122% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 23
38% more call options, than puts
Call options by funds: $6.54M | Put options by funds: $4.74M
24% more capital invested
Capital invested by funds: $1.39B → $1.73B (+$338M)
18% more funds holding
Funds holding: 153 → 181 (+28)
18% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 45
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$50.7M |
| 2 |
First Trust Advisors
Wheaton,
Illinois
|
+$39.3M |
| 3 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$17.2M |
| 4 |
GAM
Gotham Asset Management
New York
|
+$15.6M |
| 5 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
+$14.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$41.1M |
| 2 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$13.2M |
| 3 |
Bank of New York Mellon
New York
|
-$11.4M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$7.72M |
| 5 |
DFO
Duquesne Family Office
New York
|
-$7.21M |
NKTR Hedge Fund Activity: Q2 2015 in Review
181 of the 3,713 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q2 2015, worth a combined $1.73B — up 24% from $1.39B a quarter earlier.
Buyers outnumbered sellers: 51 funds opened new NKTR positions and 23 closed out — a net gain of 28 holders — while 53 added to existing stakes and 45 trimmed.
The largest buyer was BlackRock Fund Advisors, adding an estimated $50.7M. The largest seller was JP Morgan Chase, cutting an estimated $41.1M.
- 181 institutional investors held Nektar Therapeutics (NKTR) as of Q2 2015, up from 153 in Q1 2015.
- Funds reported $1.73B of Nektar Therapeutics stock for Q2 2015, up 24% quarter-over-quarter.
- 51 funds opened new Nektar Therapeutics positions in Q2 2015 and 23 closed out, a net change of +28 holders.
- The largest Nektar Therapeutics buyer in Q2 2015 was BlackRock Fund Advisors, an estimated $50.7M added.
- The largest Nektar Therapeutics seller in Q2 2015 was JP Morgan Chase, an estimated $41.1M sold.
Based on aggregated 13F filings for Q2 2015.